A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants with Treatment-resistant Depression
Official Title
A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants with Treatment-resistant DepressionPurpose
The purpose of this study is to see if esketamine nasal spray alone is effective as a medication to improve depressive symptoms in adults with treatment-resistant depression when compared with placebo nasal spray.
The duration of the study consists up to a maximum of 24 weeks.
Could this study be right for you?
• Aged 18 years or older
• Must have had no response (less than 25% improvement) to at least 2 oral antidepressant treatments in the current episode of depression